Table 1 Transplant indications

From: Hematopoietic cell transplants in Jordan: different indications from the US and EU

 

Allotransplant (1050)

Autotransplant (643)

AML

231 (22%)

–

ALL

189 (18%)

–

MDS + MPN

47 (5%)

–

CML

37 (4%)

–

Hodgkin

46 (5%)

206 (32%)

PCM

5 (0.5%)

184 (29%)

NHL

23 (2%)

113 (18%)

Solid cancera

–

140 (21%)

Hemoglobinopathy

187 (18%)

–

Bone marrow failureb

161 (16%)

–

Immune deficiencyc

51 (5%)

–

Other inherited/metabolic

16 (2%)

–

Otherd

36 (3.5%)

–

  1. AML acute myeloid leukaemia; ALL acute lymphoblastic leukaemia; MDS myelodysplastic syndrome; MPN myeloproliferative neoplasm; CML chronic myeloid leukaemia; PCM plasma cell myeloma; NHL non-Hodgkin lymphoma
  2. aSolid cancers included neuroblastoma (N = 88), germ cell tumours (N = 19), Ewing sarcoma and peripheral neuro-endocrine tumours (N = 11), medulloblastoma (N = 8), Wilm tumour (N = 5), retinoblastoma (N = 3); renal cell carcinoma (N = 3); meningeal and synovial cell sarcomas (N = 2) and choroid plexus carcinoma (N = 1)
  3. bAplastic anaemia, Fanconi anaemia and sickle cell anaemia
  4. cDoes not include 100 transplants reported telephonically
  5. dIncludes pure red cell aplasia (N = 6), congenital amegakaryocytic thrombocytopenia (N = 6), chronic granulomatous disease (N = 2); osteopetrosis (N = 2); haemophagocytic lympho-histiocytosis (N = 2)
Back to article page